Breast Cancer

P=N/A, N=5505, Active, not recruiting, University of Rostock | Trial completion date: Dec 2024 --> Jun 2025

P3, N=510, Active, not recruiting, Olema Pharmaceuticals, Inc. | Recruiting --> Active, not recruiting

P1, N=84, Active, not recruiting, Incyte Corporation | Trial completion date: Dec 2024 --> Apr 2025 | Trial primary completion date: Nov 2024 --> Apr 2025

P1, N=26, Recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Jun 2025

P2, N=87, Completed, Nancy Lin, MD | Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Aug 2024

P1/2, N=96, Not yet recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University | Initiation date: Sep 2024 --> Dec 2024

P3, N=701, Recruiting, Celcuity Inc | Trial completion date: Sep 2026 --> Dec 2026 | Trial primary completion date: Sep 2024 --> Mar 2025

P1/2, N=129, Active, not recruiting, Jules Bordet Institute | Trial completion date: Apr 2025 --> Dec 2025 | Trial primary completion date: Aug 2024 --> Mar 2025

P=N/A, N=60, Not yet recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University

P4, N=22, Recruiting, University of Michigan Rogel Cancer Center | Trial completion date: Nov 2024 --> Mar 2025 | Trial primary completion date: Nov 2024 --> Mar 2025

P2, N=121, Active, not recruiting, SCRI Development Innovations, LLC | Recruiting --> Active, not recruiting

P=N/A, N=76, Recruiting, Institut de Cancérologie de Lorraine | Active, not recruiting --> Recruiting

This study extends the understanding of the function of PUFAs metabolism in BC development, providing potential therapeutic targets and dietary guidelines for patients with TNBC and other BCs. The illustration of the hypothetical mechanism CYP2J2/EpOMEs promotes the tumorigenesis and metastasis of TNBC via PLEC/NFKB1/CXCL9 signaling pathway.

Quality of life was maintained when palbociclib was added to letrozole in Asian women with ABC. These findings are consistent with PALOMA-2 results and support the use of palbociclib as first-line treatment in postmenopausal Asian patients with ER+/HER2- ABC.

Our investigations represent two conceptual abstractions implying a link between loss of cell-cell cohesion and lobular localization of LCIS, which provide a much-needed logical foundation for studying the connections between collective cell behavior and cancer development in breast tissues. In light of the findings from our simplified modeling approach, we discuss multiple avenues for near-future research that can address and evaluate the redistribution hypothesis mathematically and empirically.

Nonetheless, other investigations have mentioned its conflicting effects on cancer prevention. Herein, we provide an updated understanding of the critical mechanisms behind the anticancer immunity mediated by Treg cells plasticity, the role of IL-35, and tactics to strengthen the immune response against malignancies, outlining major clinical trials that used Treg cells/IL-35 therapies in the three main cancer types (lung, breast, and colorectal cancers).

Across the Nordic countries, incidence of BC in women aged 80+ increased. In Denmark, rising incidence of BC is driven by the ER+/HER2- subtype in the 80+ group, which has the best prognosis and gentle treatments. More elderly BC patients will require treatment and follow-up in the future.

This study demonstrates that ketamine alleviates BC cell-induced osteoclastogenesis and tumor bone metastasis by suppressing SRC and restoring the EGR1/CST6 axis.

In women with ADH/LN most BCs occur beyond 5 years. ES regimens should therefore extend to at least 10 years and be at least biennial. Preventative therapy should be considered given the high BC SIR and ER positivity of subsequent tumours.

Surprisingly, these skipped exons and retained intron events rarely lead to substantial gene expression repression, suggesting that PRMT5 inhibition predominantly results in nuclear detention of intron-containing transcripts and the production of non-canonical isoforms with compromised protein function. Since many genes within the same DDR pathway undergo deregulated splicing, this study thus reveals additional points of vulnerability and alternative combination drug strategies that could improve the therapeutic efficacy of PRMT5 inhibitors to promote BCSC eradication.

These molecules include galectin-1, S100A10, S100A4, and S100A6. Collectively, our findings highlight the lipid metabolism reprogramming of cancer and components of the tumor microenvironment that support lung metastasis of TNBC breast cancer.

The TAIGPI can be an effective predictive strategy for the clinical prognosis of breast cancer patients, providing new insights into personalized treatment options for breast cancer patients.

Furthermore, DigNet provides unique insights into the immune response in breast cancer, derived from differential gene regulations identified in T cells. As an open-source software, DigNet offers a powerful and effective tool for generating cell specific GRN from scRNA-seq data.

In results, the combination of Na2SeO3 + BTZ reduced the expression of Bcl-XL and N-Cad causing cytotoxicity and suggested that the combination of Na2SeO3 + BTZ (IC50 = 1.40 ± 0.45 μM) could be a better option among other combinations for breast cancer therapy. Overall, the outcome indicates that the combination of BTZ with AOs may yield potential therapeutic benefit.

circUBR5 knockdown facilitated miR-340-5p-targeted CMTM6 via a ceRNA mechanism, thereby reducing c-MYC-mediated ribosome biogenesis and accelerating chemosensitization of DTX-resistant TNBC cells, which offered a theoretical guideline for clinical research on the feasibility of inhibiting ribosome biogenesis to reduce TNBC chemoresistance.

Abemaciclib+fulvestrant significantly improved PFS after disease progression on prior CDK4/6i+ET in patients with HR+, HER2- ABC, offering an additional targeted therapy option for these patients.

Additionally, in vitro fluorescence imaging studies confirmed AZBNPy's specificity for cancer cell receptors, displaying strong fluorescence in human breast cancer tissues. The clinical application of AZBNPy as an optical imaging agent holds significant promise in aiding surgeons with the precise identification and removal of cancerous tissues, potentially improving patient outcomes and survival rates.

This review emphasizes the diverse roles of CARMN across different cancers and its potential as a diagnostic and therapeutic tool. Future research should address the mechanistic details of CARMN's involvement in cancer, validate its clinical utility, and explore its therapeutic potential in combination with existing treatments.

Our results show that miR-484 may play a roll as an onco-miR in BC. Increased miR-484 and BCL2, and decreased Casp3, in breast tumor tissues suggest that Casp9 expression may increase uncontrolled cell proliferation by suppressing apoptosis in BC cells and may contribute to tumor progression.

Moreover, these findings further validated the ability of prolactin as a persuader of a more differentiated and less aggressive breast cancer phenotype. Hence, it suggested a potential implication of prolactin as a therapeutic candidate.

AuNPs can deliver miR-875-5p to BC cells, and AuNP-miR-875-5p has clinical potential for treating unresectable BC.

Our study identified the causal influence of OA on BC mediated by MDD at the genetic level. OA-Score may potentially serve as a new prognostic biomarker for OA related BC patients.

We found that the HER2 status of CTC in peripheral blood was inconsistent with the histological findings. Further research should explore the clinical significance of detecting HER2-positive CTCs, and it is desired that real-time HER2 status testing of CTCs could hold potential value for patients with breast cancer.

No long-term adverse effects on hematological or biochemical parameters or tissue levels were observed in the mice. Given these findings, this compound demonstrates significant cytotoxic effects and has the potential to serve as a promising chemotherapeutic agent, warranting further investigation at more advanced stages.

Notably, we identified a prognostic neoantigen from the TBC1D4-COMMD6 fusion that significantly improves patient prognosis and extensively binds to 16 types of HLA alleles. These highly immunogenic and tumor-specific neoantigens offer emerging targets for personalized cancer immunotherapies and act as prospective predictors for tumor survival prognosis and responses to immune checkpoint therapies.

Total CTCs in BC patients have an independent influence on PFS reduction. Higher total CTCs and MCTCs in peripheral blood are biomarkers for predicting the prognosis of BC patients. HER-2 high expression is also associated with the prognosis of the disease.

This ensures that the therapeutic action is localized, reducing systemic toxicity and enhancing treatment efficacy. These findings suggest that this neoadjuvant approach holds promise for broader applications in other cancer types.

P=N/A, N=74, Completed, Tigers Running Club | Active, not recruiting --> Completed

P2, N=100, Completed, Northwestern University | Recruiting --> Completed | Phase classification: P2b --> P2

P=N/A, N=45, Recruiting, Tethis S.p.A. | Trial completion date: Nov 2024 --> Jun 2025 | Trial primary completion date: Nov 2024 --> Jun 2025

P1/2, N=78, Recruiting, Filipa Lynce, MD | Suspended --> Recruiting

P=N/A, N=180, Not yet recruiting, Cancer Research Antwerp